{"created":"2022-01-27T02:25:54.602974+00:00","id":2002365,"links":{},"metadata":{"_buckets":{"deposit":"5664e3ae-631a-4d20-81ca-c8dceadf636e"},"_deposit":{"id":"2002365","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"2002365"},"status":"published"},"_oai":{"id":"oai:u-ryukyu.repo.nii.ac.jp:02002365","sets":["1642838163960:1642838338003","1642838403551:1642838407795"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_1551255647225":"Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway","subitem_1551255648112":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ishikawa, Chie","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Matsuda, Takehiro","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Okudaira, Taeko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tomita, Mariko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kawakami, Hirochika","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tanaka, Yuetsu","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Masuda, Masato","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ohshiro, Kazuiku","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ohta, Takao","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Mori, Naoki","creatorNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_1522299639480":"open access","subitem_1600958577026":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"bisphosphonate"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"incadronate"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"human T-cell leukaemia virus type I"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"adult T-cell leukaemia"},{"subitem_1522299896455":"en","subitem_1522300014469":"Other","subitem_1523261968819":"mevalonate"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Anti-resorptive bisphosphonates are used for the treatment of hypercalcemia and bone complications associated with malignancies and osteoporosis, but have also been shown to have anti-tumour effects in various cancers. Adult T-cell leukaemia (ATL) is a fatal T-cell malignancy caused by infection with human T-cell leukaemia virus type I (HTLV-I), and remains incurable. ATL is associated with osteolytic bone lesions and hypercalcemia, which are major factors in the morbidity of ATL. Thus, the search for anti-ATL agents that have both anti-tumour and anti-resorptive activity is warranted. The bisphosphonate agent, incadronate prevented cell growth of HTLV-I-infected T-cell lines and primary ATL cells, but not of non-infected T-cell lines or normal peripheral blood mononuclear cells. Incadronate induced S-phase cell cycle arrest and apoptosis in HTLV-I-infected T-cell lines, and treatment of these cells with substrates of the mevalonate pathway blocked the incadronate-mediated growth suppression. Incadronate also prevented the prenylation of Rap1A protein. These results demonstrated that incadronate-induced growth suppression occurs by interfering with the mevalonate pathway. Importantly, treatment with incadronate reduced tumour formation from an HTLV-I-infected T-cell line, when these cells were inoculated subcutaneously into severe combined immunodeficient mice. These findings suggest that incadronate could be potentially useful for the treatment of ATL.","subitem_description_type":"Other"},{"subitem_description":"論文","subitem_description_type":"Other"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_1522300295150":"en","subitem_1522300316516":"Blackwell Publishing"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_1551255818386":"eng"}]},"item_1617186783814":{"attribute_name":"Identifier","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/20.500.12000/2608"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_1522646500366":"ISSN","subitem_1522646572813":"0007-1048"},{"subitem_1522646500366":"NCID","subitem_1522646572813":"AA00574570"}]},"item_1617186941041":{"attribute_name":"Source Title","attribute_value_mlt":[{"subitem_1522650068558":"en","subitem_1522650091861":"British journal of haematology"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueNumber":"3","bibliographicPageEnd":"432","bibliographicPageStart":"424","bibliographicVolumeNumber":"136"}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_1522305645492":"AM","subitem_1600292170262":"http://purl.org/coar/version/c_ab4af688f83e57aa"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_1522306287251":{"subitem_1522306382014":"URI","subitem_1522306436033":"http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2006.06445.x"}},{"subitem_1522306287251":{"subitem_1522306382014":"DOI","subitem_1522306436033":"10.1111/j.1365-2141.2006.06445.x"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"BJHv136n3p424-fig.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2002365/files/BJHv136n3p424-fig.pdf"},"version_id":"75150257-a5cc-4ad6-8a75-609651a954a5"},{"accessrole":"open_access","filename":"BJHv136n3p424.pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://u-ryukyu.repo.nii.ac.jp/record/2002365/files/BJHv136n3p424.pdf"},"version_id":"d44dc56e-01f3-418c-b0f8-36e5cd647674"}]},"item_title":"Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway","item_type_id":"15","owner":"1","path":["1642838338003","1642838407795"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2007-12-10"},"publish_date":"2007-12-10","publish_status":"0","recid":"2002365","relation_version_is_last":true,"title":["Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-08-03T05:33:09.557771+00:00"}